ArticleJournal of virology1999
Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors.
Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 132 citations in OpenAlex.
- HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages.Nature communications · 2024Article
- Article
- Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.Molecular therapy. Methods & clinical development · 2023Article
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.Pharmaceutics · 2023Review
- Laboratory-Scale Lentiviral Vector Production and Purification for EnhancedMolecular therapy. Methods & clinical development · 2020Article
- Improved third-generation lentiviral packaging with pLKO.1C vectors.BioTechniques · 2020Article
- Article
- Development of a laboratory scalable process for enhancing lentivirus production by transient transfection of HEK293 adherent cultures.Gene therapy · 2019Article
- The Improvement and Application of Lentivirus-Mediated Gene Transfer and Expression System in Penaeid Shrimp Cells.Marine biotechnology (New York, N.Y.) · 2019Article
- DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.Molecular biotechnology · 2018Article
- Assessment of selected media supplements to improve F/HN lentiviral vector production yields.Scientific reports · 2017Article
- CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo.PLoS pathogens · 2017Article
- Use of Lentiviral Particles As a Cell Membrane-Based mFasL Delivery System forFrontiers in immunology · 2017Article
- Production of lentiviral vectors.Molecular therapy. Methods & clinical development · 2016Review
- Myosin VI mediates the movement of NHE3 down the microvillus in intestinal epithelial cells.Journal of cell science · 2014Article
- A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors.BioResearch open access · 2013Article
- Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation.Journal of virology · 2012Article
- Production of lentiviral vectors for transducing cells from the central nervous system.Journal of visualized experiments : JoVE · 2012Article
- Using Pulmozyme DNase treatment in lentiviral vector production.Human gene therapy methods · 2012Article
- Production of CGMP-Grade Lentiviral Vectors.BioProcess international · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of human immunodeficiency type 1 (HIV-1)-based vectors have recently been shown to transduce nondividing cells in vivo as well as in vitro. However, if these vectors are to be considered for eventual clinical use, a major consideration is to reduce the probability of unintended generation of replication-competent virus. This can be achieved by eliminating viral genetic elements involved in the generation of replication-competent virus without impairing vector production. We have designed a system to transiently produce HIV-1-based vectors by using expression plasmids encoding Gag, Pol, and Tat of HIV-1 under the control of the cytomegalovirus immediate-early promoter. Our data show that the best vector yield is achieved in the presence of the Rev/Rev-responsive element (RRE) system. However, the constitutive transport element of Mason-Pfizer monkey virus can substitute for RRE and Rev at least to some extent, whereas the posttranscriptional regulatory element of human hepatitis B virus appeared to be inefficient. In addition, we show that high-titer virus preparations can be obtained in the presence of sodium butyrate, which activates the expression of both the packaging construct and the vector genome. Finally, our results suggest that efficient infectivity of vectors defective in the accessory proteins Vif, Vpr, Vpu, and Nef depends on the nature of the target cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.